Unicycive discloses securities class action over phosphate binder NDA statements

Unicycive Therapeutics, Inc.

Lawsuit filed in U.S. District Court for Northern District of California against company and certain officers.
Alleges violations of federal securities laws regarding public statements on NDA for oxylanthanum carbonate phosphate binder.
Product targets hyperphosphatemia in chronic kidney disease patients on dialysis.
Company believes claims are meritless and intends to vigorously defend the lawsuit.
Lawsuit became known to company on August 15, 2025.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.